Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study [PDF]
BMC Pulmonary Medicine, 2011 Background The inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and the long-acting β2-agonist (LABA) formoterol fumarate (formoterol) are being made available as a combination product (fluticasone/formoterol, flutiform®) in a single ...
McAulay Kirsten +3 more
doaj +4 more sources
Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial [PDF]
Therapeutic Advances in Respiratory Disease, 2018 Background: The efficacy and safety of fluticasone propionate/formoterol fumarate pressurized metered-dose inhaler (pMDI) (fluticasone/formoterol; Flutiform ® ; 100/10 µg b.i.d.) was compared with fluticasone propionate (Flixotide ® Evohaler ® pMDI; 100 ...
Anna Płoszczuk +4 more
doaj +2 more sources
Combined azelastine fluticasone nasal spray versus fluticasone propionate nasal spray in postoperative management of central compartment atopic disease (CCAD) [PDF]
Frontiers in PharmacologyBackgroundCentral compartment atopic disease (CCAD) is a subtype of chronic rhinosinusitis with nasal polyps (CRSwNP), distinguished by polypoid changes in the middle turbinates, superior nasal septum, and/or superior turbinates.ObjectiveThe aim of this ...
Samy Elwany +4 more
doaj +2 more sources
Journal of Asthma and Allergy, 2023 Wenyuan Qi,1,2 Yue Liu,1,2 Wei Xue,1,2 Kexin Li,1,2 J Christopher Gorski,3 Mark Liu,3 Tieliang Yan,3 Duc Tung Nguyen,4 Rajesh Kumar Ramalingam5 1Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine ...
Qi W +8 more
doaj +3 more sources
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone [PDF]
New England Journal of Medicine, 2016 The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled
iemoli
exaly +10 more sources
Single-Cell Sequencing of Lung Macrophages and Monocytes Reveals Novel Therapeutic Targets in COPD
Cells, 2023 Background: Macrophages and monocytes orchestrate inflammatory processes in the lungs. However, their role in the pathogenesis of chronic obstructive pulmonary disease (COPD), an inflammatory condition, is not well known.
Yushan Hu +7 more
doaj +1 more source
Immunity, Inflammation and Disease, 2023 MP‐AzeFlu (intranasal fluticasone and azelastine) has been widely studied and has demonstrated efficacy in Allergic rhinitis with a superior effect compared to these drugs administered individually; however, the mechanism by which MP‐AzeFlu produces this
Sonia Vicens‐Artes +8 more
doaj +1 more source
Indian Journal of Paediatric Dermatology, 2022 Background: There is sparsity of data on the comparative effectiveness of topical steroids and topical tacrolimus in the treatment of pediatric atopic dermatitis (AD) and prevention of its relapse.
Sanjeev Handa +3 more
doaj +1 more source
Long-acting β2-agonists increase fluticasone propionate-induced mitogen-activated protein kinase phosphatase 1 (MKP-1) in airway smooth muscle cells. [PDF]
PLoS ONE, 2013 Mitogen-activated protein kinase phosphatase 1 (MKP-1) represses MAPK-driven signalling and plays an important anti-inflammatory role in asthma and airway remodelling. Although MKP-1 is corticosteroid-responsive and increased by cAMP-mediated signalling,
Melanie Manetsch +7 more
doaj +1 more source
Frontiers in Cellular and Infection Microbiology, 2020 Human rhinoviruses (HRVs) are associated with acute exacerbations in patients with chronic obstructive pulmonary disease (COPD) and asthma, which are accompanied by mucus hypersecretion.
Ying Wang +3 more
doaj +1 more source